FDA Grants Fast Track Designation to ERAS-0015 for Metastatic Pancreatic Cancer

The FDA has granted Fast Track designation to ERAS-0015, an investigational oral pan-RAS molecular glue, for the treatment of patients with metastatic pancreatic adenocarcinoma. The designation follows preliminary phase 1 findings showing antitumor activity in patients with previously treated KRAS G12X pancreatic ductal adenocarcinoma (PDAC).¹

ERAS-0015 is designed to inhibit RAS signaling across multiple RAS alterations rather than targeting a single KRAS mutation. The broader approach could be particularly relevant in pancreatic cancer, where RAS pathway alterations are common and treatment options remain limited after disease progression.¹

Early AURORAS-1 Data Show Responses in KRAS G12X PDAC

This designation follows updated preliminary results from the ongoing phase 1 AURORAS-1 trial (NCT06983743) evaluating ERAS-0015 in patients with RAS-mutant solid tumors.^1,3

Among patients with second-line or later KRAS G12X PDAC treated with the recommended dose for expansion of 32 mg once daily, ERAS-0015 produced a 57% overall response rate at or beyond 8 weeks. This analysis included 7 evaluable patients and incorporated both confirmed and unconfirmed responses.³

At the May 25, 2026, data cutoff, 6 of 7 patients treated at 32 mg once daily remained on treatment. Across dose levels, all patients who had achieved either a confirmed or unconfirmed response were still receiving ERAS-0015.³

The findings remain early, and the small patient population limits conclusions regarding the durability and magnitude of benefit. Longer follow-up and larger cohorts will be needed to establish whether the responses translate into sustained clinical benefit.

ERAS-0015 was generally well tolerated at the recommended expansion doses. Treatment-related adverse events were primarily low grade, and no dose-limiting toxicities or treatment-related discontinuations were reported in the July 2026 analysis. Median relative dose intensity was 100% at both the 24-mg and 32-mg once-daily doses.³

Pan-RAS Inhibition Broadens the Targeting Strategy

RAS signaling has historically been difficult to target directly, although the development of mutation-specific KRAS inhibitors has begun to change that treatment landscape in select tumors.

As a pan-RAS molecular glue, ERAS-0015 is designed to inhibit signaling across RAS-driven cancers instead of restricting activity to a single mutation subtype.¹

That strategy is particularly relevant in PDAC, where molecular heterogeneity can limit the number of patients eligible for mutation-specific therapies. A broader RAS-directed approach could potentially extend targeted treatment to a larger population if clinical efficacy is confirmed.

For patients with metastatic pancreatic cancer, systemic chemotherapy remains the backbone of treatment. Current first-line options include NALIRIFOX, FOLFIRINOX, and gemcitabine plus nab-paclitaxel, depending on patient characteristics and performance status. Despite these regimens, metastatic disease remains difficult to treat, and the National Cancer Institute continues to identify clinical trial enrollment as an important consideration for patients with advanced disease.⁴

Development Moving Toward Phase 3 Testing

A phase 3 trial in first-line PDAC is planned for 2027. The company also expects to initiate a potentially registration-enabling study in second-line or later non-small cell lung cancer in the first half of 2027, followed by another phase 3 lung cancer study between the second half of 2027 and the first half of 2028.³

Additional AURORAS-1 monotherapy and combination data are expected during the first half of 2027.¹

For oncology pharmacists, continued development of ERAS-0015 will place attention on tolerability, adherence, drug interaction considerations, and how an oral targeted agent could ultimately be integrated with established chemotherapy regimens. As later-phase trials begin, the durability of response and the ability to identify patients most likely to benefit will become central questions.

The FDA Fast Track designation provides a regulatory pathway for closer FDA interaction as ERAS-0015 moves from early-phase testing toward pivotal development in a disease with substantial unmet need.^1,2

REFERENCES

1. Erasca. Erasca granted FDA Fast Track designation for pan-RAS molecular glue ERAS-0015 in patients with metastatic pancreatic adenocarcinoma. Published August 24, 2026. Accessed August 24, 2026. https://www.biospace.com/press-releases/erasca-granted-fda-fast-track-designation-for-pan-ras-molecular-glue-eras-0015-in-patients-with-metastatic-pancreatic-adenocarcinoma

2. US Food and Drug Administration. Fast Track. Accessed August 24, 2026.https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/fast-track

3. Erasca. Erasca announces updated preliminary phase 1 data and registration-enabling plans for potentially best-in-class pan-RAS molecular glue ERAS-0015 in KRAS-mutant solid tumors. Published July 13, 2026. Accessed August 24, 2026. https://investors.erasca.com/news-releases/news-release-details/erasca-announces-updated-preliminary-phase-1-data-and

4. PDQ Adult Treatment Editorial Board. Pancreatic Cancer Treatment (PDQ®): Health Professional Version. In: PDQ Cancer Information Summaries. Bethesda (MD): National Cancer Institute (US); February 12, 2025. Accessed August 24th, 2026.